PEGPH20

DRUG13 trials

Sponsors

Halozyme Therapeutics, SWOG Cancer Research Network, Memorial Sloan Kettering Cancer Center, Andrew Ko, Hoffmann-La Roche

Conditions

AdenocarcinomaAdvanced Pancreatic Ductal AdenocarcinomaCholangiocarcinoma Non-resectableCholangiocarcinoma, ExtrahepaticCholangiocarcinoma, IntrahepaticGallbladder AdenocarcinomaGastric CancerMetastatic Pancreatic Adenocarcinoma

Phase 1

Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors

CompletedNCT00834704

Halozyme TherapeuticsSolid Tumor

Start: 2009-02-28End: 2012-11-30Updated: 2013-03-26

Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors

CompletedNCT01170897

Halozyme TherapeuticsSolid Tumor

Start: 2010-07-31End: 2014-01-31Updated: 2014-01-29

Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer

CompletedNCT01453153

Halozyme TherapeuticsStage IV Pancreatic Cancer

Start: 2011-09-30End: 2015-05-31Updated: 2018-11-30

S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer

CompletedNCT01959139

SWOG Cancer Research NetworkMetastatic Pancreatic Adenocarcinoma

Start: 2014-01-23End: 2023-11-09Updated: 2024-02-09

A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors

CompletedNCT02563548

Halozyme TherapeuticsGastric Cancer, NSCLC

Start: 2015-10-22End: 2019-03-26Updated: 2020-02-07

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

CompletedNCT03193190

Hoffmann-La RochePancreatic Adenocarcinoma

Start: 2017-07-05End: 2025-02-27Updated: 2025-11-21

Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

TerminatedNCT03267940

Halozyme TherapeuticsCholangiocarcinoma, Extrahepatic, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma Non-resectable +1

Start: 2017-10-02End: 2019-11-11Updated: 2020-02-07

Phase 2

PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer

CompletedNCT01839487

Halozyme TherapeuticsMetastatic Pancreatic Cancer

Start: 2013-05-14End: 2018-09-26Updated: 2020-07-20

PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma

TerminatedNCT02487277

Andrew KoAdenocarcinoma

Start: 2015-07-14End: 2018-05-18Updated: 2020-01-02

Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC

Pancreatic Cancer Research TeamPancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Neoplasms

Start: 2019-05-01End: 2021-01-31Target: 35Updated: 2019-05-07

Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma

TerminatedNCT03979066

Gulam ManjiPancreatic Ductal Adenocarcinoma

Start: 2019-11-01End: 2019-11-03Updated: 2020-12-23

Unknown Phase

Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection

CompletedNCT02241187

Memorial Sloan Kettering Cancer CenterPancreatic Cancer

Start: 2014-09-12End: 2016-09-13Updated: 2017-09-27

Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma

Active, not recruitingNCT02921022

Memorial Sloan Kettering Cancer CenterAdvanced Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer

Start: 2016-10-31End: 2026-10-31Target: 110Updated: 2025-11-26

Related Papers

Atezolizumab and Motixafortide, Cobimetinib or Simlukafusp Alfa in Pretreated Advanced Pancreatic Cancer: Phase I/IIb MORPHEUS-PDAC Umbrella Study.

2026-02-25

Magnetic resonance imaging of tumor response to stroma-modifying pegvorhyaluronidase alpha (PEGPH20) therapy in early-phase clinical trials.

2024-05-214 citations

Abstract CT212: Phase Ib/II, global, open-label, randomized evaluation of atezolizumab (atezo) + etrumadenant (etruma) + chemotherapy (chemo) vs chemo alone in MORPHEUS-PDAC

Cancer Research2024-04-05

Phase 2 study of preoperative chemotherapy with nab‐paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node‐positive pancreatic ductal adenocarcinoma

Cancer Medicine2023-05-034 citations

Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform

The Oncologist2023-03-2048 citations

Phase II study of PEGPH20 plus pembrolizumab for patients (pts) with hyaluronan (HA)-high refractory metastatic pancreatic adenocarcinoma (mPC): PCRT16-001.

Journal of Clinical Oncology2022-01-1917 citations

Safety and pharmacokinetics of docetaxel in combination with pegvorhyaluronidase alfa in patients with non‐small cell lung cancer

Clinical and Translational Science2021-05-1310 citations

Blood-based extracellular matrix biomarkers as predictors of survival in patients with metastatic pancreatic ductal adenocarcinoma receiving pegvorhyaluronidase alfa.

2021-01-2120 citations

259 Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) + selicrelumab (seli) + gemcitabine+nab-paclitaxel (gem+nabP) or bevacizumab (bev) vs control in MORPHEUS-PDAC, -TNBC and -CRC

Regular and Young Investigator Award Abstracts2020-11-012 citations

Abstract CT201: Phase Ib/II open-label, randomized evaluation of atezolizumab + cobimetinib vs control in MORPHEUS-NSCLC (non-small cell lung cancer), MORPHEUS-PDAC (pancreatic ductal adenocarcinoma) and MORPHEUS-GC (gastric cancer)

Cancer Research2020-08-154 citations

Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + PEGPH20 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).

Journal of Clinical Oncology2020-05-208 citations

Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo) + BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric cancer (M-GC).

Journal of Clinical Oncology2020-02-017 citations

PCRT16-001: Phase II study of PEGPH20 plus pembrolizumab for patients (pts) with hyaluronan (HA)-high refractory metastatic pancreatic ductal adenocarcinoma (mPDA).

Journal of Clinical Oncology2020-02-016 citations

Exposure-response (E-R) analysis of efficacy of pegvorhyaluronidase alfa (PEGPH20) in combination with nab-paclitaxel + gemcitabine (AG) in patients (Pts) with metastatic pancreatic ductal adenocarcinoma.

Journal of Clinical Oncology2019-05-20

MORPHEUS: A phase Ib/II study platform evaluating the safety and clinical efficacy of cancer immunotherapy (CIT)–based combinations in gastrointestinal (GI) cancers.

Journal of Clinical Oncology2019-01-2914 citations

Plasma hyaluronan is a predictive marker for pegvorhyaluronidase alfa (PEGPH20; PVHA) response in a phase II study of pancreatic ductal adenocarcinoma (PDAC).

Journal of Clinical Oncology2019-01-291 citations

Halo 110-101: Early safety results of pegvorhyaluronidase alfa (PEGPH20; PVHA) + cisplatin (C) + gemcitabine (G) ± atezolizumab (ATZ) in patients (pts) with locally advanced or metastatic cholangiocarcinoma (CCA) and gallbladder cancer (GBC).

Journal of Clinical Oncology2019-01-29

MORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types

Annals of Oncology2018-10-0119 citations

A pilot study of gemcitabine, nab-paclitaxel, PEGPH20 (PAG) and rivaroxaban for advanced pancreatic adenocarcinoma: Interim safety and efficacy analysis

Annals of Oncology2018-10-012 citations

Abstract 2740: PEGylated recombinant hyaluronidase PH20 (pegvorhyaluronidase alfa PEGPH20) converts HA-rich tumors from resistant to sensitive to anti-PD-L1 immunotherapy in murine syngeneic breast cancer models

Cancer Research2018-07-012 citations

17 more papers not shown